Article Text
Statistics from Altmetric.com
Antiphospholipid syndrome (APS) is a heterogeneous entity with a wide variation in clinical course and laboratory profile. It is accepted that the presence of antiphospholipid antibodies (aPL) confers a higher risk for both thrombosis and pregnancy morbidity, but quantifying such a risk is still a challenge. As a consequence, clinicians are unable to tailor the treatment according to the risk.
Recently, Otomo et al 1 developed and validated the so-called ‘antiphospholipid score’ (aPL-S) by testing multiple aPL and evaluating the aPL-S efficacy for the diagnosis of APS and predictive value for thrombosis. This score was shown to be a useful quantitative index for diagnosing APS and to be valuable as a predictive marker for thrombosis in autoimmune diseases.
In order to independently validate the aPL-S, we …
Footnotes
-
Competing interests All authors declare not to have any financial or other relationships that might lead to a conflict of interest. This manuscript has been read and approved by all authors. The manuscript has not been published or submitted elsewhere.
-
Ethics approval Ethics approval was obtained from the Guy’s and St Thomas’ Ethics Committee and all patients involved in this study gave their written consent.
-
Provenance and peer review Not commissioned; externally peer reviewed.